

New drug approved for lack of certain white blood cells

August 30 2012

(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.

Neutropenia, sometimes triggered by certain [chemotherapy drugs](#), is characterized by a decrease in infection-fighting [white blood cells](#) called neutrophils. Tbo-filgrastim stimulates the bone marrow to increase output of neutrophils. The new drug, injected about 24 hours after chemotherapy is administered, is meant for adults who do not have cancers of the blood or bone marrow, the FDA said.

Tbo-filgrastim was evaluated among 348 adults with [advanced breast cancer](#) who received the chemotherapy drugs doxorubicin and docetaxel. People who received the tbo-filgrastim recovered from severe neutropenia in an average of 1.1 days, compared with 3.8 days among adults given a placebo, the agency said.

Bone pain was the most common side effect of the new drug observed in clinical testing, the FDA said.

Tbo-filgrastim is produced by Sicor Biotech, a unit of the Israeli pharmaceutical firm Teva Corp.

More information: To learn more about [neutropenia](#), visit the Mayo Clinic.

Copyright © 2012 [HealthDay](#). All rights reserved.

Citation: New drug approved for lack of certain white blood cells (2012, August 30) retrieved 23 January 2023 from <https://medicalxpress.com/news/2012-08-drug-lack-white-blood-cells.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.